SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Syndax Pharmaceuticals Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$13.09+0.19 (+1.47%)
Close on Oct 19, 2026
- Market cap
- $1.16B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.21 (−8.46%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Syndax Pharmaceuticals Inc grew revenue 222.7% to $252.25M over the twelve months to Jun 30, 2026. Free cash flow was -$323.17M.
Revenue
$252.25M
+222.7% vs. a year earlier
Operating income
-$194.17M
TTM Q2 2026
Free cash flow
-$323.17M
FY2025
EPS, diluted
-$2.51
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.16B
- P/E ratio
- –
- Price to sales
- 4.62
- Price to book
- 77.15
- Dividend yield
- –
- Free cash flow yield
- -27.74%
Fundamentals
- Revenue
- $252.25M
- Net income
- -$220.77M
- EPS, diluted
- -$2.51
- Free cash flow
- -$323.17M
- Book value per share
- $0.17
- Diluted shares
- 89M
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
$252.25M+222.7% YoY
Operating income
-$194.17M
Net income
-$220.77M
EPS, diluted
-$2.51
Free cash flow
–
Reported periodTrailing twelve months